JPH11511174A - 血管形成の促進方法 - Google Patents
血管形成の促進方法Info
- Publication number
- JPH11511174A JPH11511174A JP9509515A JP50951597A JPH11511174A JP H11511174 A JPH11511174 A JP H11511174A JP 9509515 A JP9509515 A JP 9509515A JP 50951597 A JP50951597 A JP 50951597A JP H11511174 A JPH11511174 A JP H11511174A
- Authority
- JP
- Japan
- Prior art keywords
- relaxin
- treatment
- vegf
- administering
- recombinant human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Surgery (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.治療的に有効な量のリラキシンを投与することを含む、感染症または虚血 性創傷の治療を要する哺乳動物における感染症または虚血性創傷の治療方法。 2.少なくとも約1ng/mlの血清濃度を維持するのに十分な量のリラキシンの 投与を含む、請求項1に記載の治療方法。 3.組換えヒトリラキシン(H2)の投与を含む、請求項1に記載の治療方法。 4.組換えヒトリラキシン(H2)の投与を含む、請求項2に記載の治療方法。 5.前記リラキシンを非経口的に投与する、請求項3に記載の治療方法。 6.前記リラキシンを皮下注射により投与する、請求項5に記載の治療方法。 7.前記リラキシンを吸入により患者の気道へ投与する、請求項3に記載の治 療方法。 8.前記の感染症または虚血性創傷の損傷が、循環不全による酸素欠乏の結果 である、請求項3に記載の治療方法。 9.前記の循環不全による酸素欠乏が、疾患の結果である、請求項8に記載の 治療方法。 10.該疾患が強皮症または糖尿病である、請求項9に記載の治療方法。 11.該創傷が虚血性潰瘍である、請求項1に記載の治療方法。 12.治療的に有効な量のリラキシンを投与することを含む、血管形成の促進を 要する哺乳動物における血管形成の促進方法。 13.少なくとも約1ng/mlの血清濃度を維持するのに十分な量のリラキシンの 投与を含む、請求項12に記載の方法。 14.組換えヒトリラキシン(H2)の投与を含む、請求項12に記載の方法。 15.組換えヒトリラキシン(H2)の投与を含む、請求項13に記載の方法。 16.前記リラキシンを非経口的に投与する、請求項14に記載の方法。 17.前記リラキシンを皮下注射により投与する、請求項16に記載の方法。 18.前記リラキシンを吸入により患者の気道へ投与する、請求項14に記載の方 法。 19.感染症または虚血性創傷の治療用の医薬を製造するためにリラキシンを使 用する方法。 20.リラキシンが組換えヒトリラキシン(H2)である、請求項19に記載の方法。 21.血管形成の促進用の医薬を製造するためにリラキシンを使用する方法。 22.リラキシンが組換えヒトリラキシン(H2)である、請求項21に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US235595P | 1995-08-15 | 1995-08-15 | |
US60/002,355 | 1995-08-15 | ||
PCT/US1996/013321 WO1997006814A1 (en) | 1995-08-15 | 1996-08-15 | Method of promoting angiogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11511174A true JPH11511174A (ja) | 1999-09-28 |
JP4568383B2 JP4568383B2 (ja) | 2010-10-27 |
Family
ID=21700396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50951597A Expired - Lifetime JP4568383B2 (ja) | 1995-08-15 | 1996-08-15 | 血管形成の促進方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US6211147B1 (ja) |
EP (1) | EP0845992B1 (ja) |
JP (1) | JP4568383B2 (ja) |
AT (1) | ATE228004T1 (ja) |
AU (1) | AU6777196A (ja) |
CA (1) | CA2229479C (ja) |
DE (1) | DE69624925T2 (ja) |
ES (1) | ES2187667T3 (ja) |
WO (1) | WO1997006814A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005519101A (ja) * | 2002-03-05 | 2005-06-30 | ジェイモナト ソシエテ ペル アチオニ | Plgf−1を含む医薬品及び化粧品組成物 |
JP2011520902A (ja) * | 2008-05-16 | 2011-07-21 | コーセラ,インコーポレーテッド | 創傷の治癒を促進する方法 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2397200C (en) * | 2000-02-09 | 2010-11-23 | Connetics Corporation | Use of relaxin to treat diseases related to vasoconstriction |
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
EP1765149B1 (en) * | 2004-03-19 | 2016-09-28 | University Of Pittsburgh | Use of relaxin to increase arterial compliance |
AU2005247332A1 (en) * | 2004-04-30 | 2005-12-08 | Corthera, Inc. | Methods and compositions for control of fetal growth via modulation of relaxin |
US7893244B2 (en) * | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
BRPI0610499A2 (pt) * | 2005-04-12 | 2010-06-22 | Intradigm Corp | moléculas de ácido nucléico , composições e usos das referidas moléculas |
US20060281669A1 (en) * | 2005-06-13 | 2006-12-14 | Yue Samuel K | Method and compositions for the treatment of diabetes and related complications |
WO2007027168A1 (en) * | 2005-08-29 | 2007-03-08 | Carrier Corporation | Compressor muffler |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
CA2724540C (en) | 2008-05-16 | 2014-07-08 | Corthera, Inc. | Treating dyspnea associated with acute heart failure with relaxin |
CA2724542A1 (en) * | 2008-05-16 | 2009-11-19 | Corthera, Inc. | Method of administering relaxin to reduce cervical dilation |
BRPI0805852A8 (pt) * | 2008-09-05 | 2021-06-29 | Univ Rio De Janeiro | polímeros ácidos protéicos, processos de produção, uso de polímeros ácidos protéicos, composição farmacêutica e método de tratamento |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD |
AU2010278894B2 (en) | 2009-07-30 | 2014-01-30 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
HRP20240267T1 (hr) | 2010-08-17 | 2024-05-10 | Ambrx, Inc. | Modificirani relaksin polipeptidi i njihove uporabe |
WO2013033324A2 (en) * | 2011-08-31 | 2013-03-07 | University Of Florida Research Foundation, Inc. | Materials and methods for modulating activity of bone marrow derived cells |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9526762B1 (en) * | 2013-08-09 | 2016-12-27 | William Marsh Rice University | Multidomain peptides for promoting angiogenesis |
US11161891B2 (en) | 2015-12-09 | 2021-11-02 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023321A (en) | 1982-12-13 | 1991-06-11 | Howard Florey Institute Of Experimental Physiology & Medicine | Molecular cloning and characterization of a further gene sequence coding for human relaxin |
US5023088A (en) * | 1987-06-25 | 1991-06-11 | Alza Corporation | Multi-unit delivery system |
JP2815649B2 (ja) * | 1988-02-26 | 1998-10-27 | ジェネンテク,インコーポレイテッド | ヒトレラキシン製剤 |
GB8907799D0 (en) * | 1989-04-06 | 1989-05-17 | Erba Carlo Spa | Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases |
AU623518B2 (en) | 1989-05-04 | 1992-05-14 | Genentech Inc. | Processes and compositions for the isolation of human relaxin |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5166191A (en) | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
US5478807A (en) | 1991-08-19 | 1995-12-26 | Genentech, Inc. | Use of relaxin in the treatment of bradycardia |
EP0675732B1 (en) | 1993-07-27 | 2006-06-28 | Mario Bigazzi | Use of relaxin in the manufacture of therapeutic agents |
US5811395A (en) * | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
US5753623A (en) * | 1995-06-07 | 1998-05-19 | Connetics Corporation | Method of treatment for depression |
US5911997A (en) | 1995-06-07 | 1999-06-15 | Connetics Corporation | Relaxin-like factor and methods and uses thereof |
-
1996
- 1996-08-15 ES ES96928212T patent/ES2187667T3/es not_active Expired - Lifetime
- 1996-08-15 US US08/698,359 patent/US6211147B1/en not_active Expired - Lifetime
- 1996-08-15 AU AU67771/96A patent/AU6777196A/en not_active Abandoned
- 1996-08-15 JP JP50951597A patent/JP4568383B2/ja not_active Expired - Lifetime
- 1996-08-15 EP EP96928212A patent/EP0845992B1/en not_active Expired - Lifetime
- 1996-08-15 WO PCT/US1996/013321 patent/WO1997006814A1/en active IP Right Grant
- 1996-08-15 DE DE69624925T patent/DE69624925T2/de not_active Expired - Lifetime
- 1996-08-15 CA CA2229479A patent/CA2229479C/en not_active Expired - Lifetime
- 1996-08-15 AT AT96928212T patent/ATE228004T1/de active
-
2001
- 2001-02-08 US US09/780,758 patent/US6780836B2/en not_active Expired - Lifetime
-
2004
- 2004-04-05 US US10/818,859 patent/US20040192606A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005519101A (ja) * | 2002-03-05 | 2005-06-30 | ジェイモナト ソシエテ ペル アチオニ | Plgf−1を含む医薬品及び化粧品組成物 |
JP2010116405A (ja) * | 2002-03-05 | 2010-05-27 | Geymonat Spa | Plgf−1を含む医薬品及び化粧品組成物 |
JP2011520902A (ja) * | 2008-05-16 | 2011-07-21 | コーセラ,インコーポレーテッド | 創傷の治癒を促進する方法 |
JP2014129392A (ja) * | 2008-05-16 | 2014-07-10 | Corthera Inc | 創傷の治癒を促進する方法 |
JP2016179990A (ja) * | 2008-05-16 | 2016-10-13 | コーセラ,インコーポレーテッド | 創傷の治癒を促進する方法 |
Also Published As
Publication number | Publication date |
---|---|
US20010018418A1 (en) | 2001-08-30 |
EP0845992A1 (en) | 1998-06-10 |
ES2187667T3 (es) | 2003-06-16 |
AU6777196A (en) | 1997-03-12 |
JP4568383B2 (ja) | 2010-10-27 |
EP0845992B1 (en) | 2002-11-20 |
EP0845992A4 (en) | 2000-04-19 |
US6780836B2 (en) | 2004-08-24 |
US6211147B1 (en) | 2001-04-03 |
DE69624925D1 (de) | 2003-01-02 |
WO1997006814A1 (en) | 1997-02-27 |
DE69624925T2 (de) | 2003-09-04 |
CA2229479A1 (en) | 1997-02-27 |
ATE228004T1 (de) | 2002-12-15 |
CA2229479C (en) | 2010-03-30 |
US20040192606A1 (en) | 2004-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4568383B2 (ja) | 血管形成の促進方法 | |
EP0309100B1 (en) | Use of amylin or CGRP for the treatment of diabetes mellitus | |
KR101058467B1 (ko) | 부신피질 자극 호르몬 유사체 및 관련 방법 | |
US5922757A (en) | Treatment and prevention of hepatic disorders | |
US6187906B1 (en) | Methods to improve neural outcome | |
Bitar | Insulin and glucocorticoid-dependent suppression of the IGF-I system in diabetic wounds | |
EP1253929A1 (en) | Use of relaxin to treat diseases related to vasoconstriction | |
JP2002523465A (ja) | 内皮ソマトスタチン受容体の選択的処理 | |
JP2009523818A (ja) | 虚血性疾患からの保護方法 | |
JP5400006B2 (ja) | 虚血性疾患の予防または治療剤 | |
US6943147B2 (en) | Cancer treatment using proANP peptides | |
EP0855916B1 (en) | Pharmaceutical composition containing an activin stimulator | |
US9101593B2 (en) | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment | |
US8361966B2 (en) | Use of interleukin-11 as therapeutic agent for heart disease | |
EP1214347B1 (en) | Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs | |
US7364722B2 (en) | Pharmaceutical and cosmetic compositions comprising plgf-1 | |
US8703693B2 (en) | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment | |
EP1072609A2 (en) | Cytoprotective agents comprising prosaposin-related peptides | |
AU2003200309B2 (en) | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases | |
US20030207811A1 (en) | Method of treating retinopathy of prematurity using somatostatin analogs | |
JP2688733B2 (ja) | 消化管粘膜障害の予防及び治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070221 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070905 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080130 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080313 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080319 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090529 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090603 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090804 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100614 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100809 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130813 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |